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Abstract
Background: Hemorrhagic fever with renal syndrome (HFRS) has become an important public health concern
because of the high incidence and mortality rates, and limited treatment and vaccination. Until now, clinical studies
on characteristics and outcomes in critical patients with HFRS have been limited. The aim of this study was to
observe the clinical characteristics and cumulative proportions surviving and explore the predictive effects and risk
factors for prognosis.
Methods: A detailed retrospective analysis of clinical records for critical HFRS patients was conducted. The patients
enrolled were treated in the centre for infectious diseases, Tangdu Hospital, between January 2008 and August
2012. The clinical characteristics between the survivors and non-survivors were compared by Student’s t-test or
Chi-square test. The risk clinical factors for prognosis were explored by logistic regression analysis. The predictive
effects of prognosis in clinical and laboratory parameters were analyzed by receiver operating characteristic (ROC)
curves. The cumulative proportions surviving at certain intervals in the critical patients were observed by
Kaplan-Meier survival analysis.
Results: Of the 75 patients enrolled, the cumulative proportion surviving was 70.7% at the second week interval,
with a 28-day mortality rate of 36.3%. The non-survivors tended to have higher frequencies of agitation, dyspnea,
conjunctival hemorrhage, coma, cardiac failure, acute respiratory distress syndrome (ARDS) and encephalopathy
(P < .05). ARDS, conjunctival hemorrhage and coma were risk factors for death in the critical patients with HFRS. The
non-survivors were found to have lower serum creatinine (Scr) levels (P < .001) and higher incidences of prolonged
prothrombin time (PT) (P = .006), activated partial thromboplastin time (APTT) (P = .003) and elevated white blood
cells (WBC) levels (P = .005), and the laboratory parameters mentioned above reached statistical significance for
predicting prognosis (P < .05).
Conclusion: The high fatality in critical patients with HFRS underscores the importance of clinicians’ alertness to the
occurrence of potentially fatal complications and changes in biochemical status to ensure that timely and
systematically supportive treatment can be initiated when necessary.
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Background
Hemorrhagic fever with renal syndrome (HFRS) is a rodent-
borne disease caused by Hantavirus [1,2]. Hantaviruses are
carried by rodents, and transmission to humans is caused
by the inhalation of infected rodent excreta [3]. China is
the most severe endemic area of HFRS in the world, with
30,000-50,000 cases reported annually, which account
for > 90% of total numbers worldwide [4,5]. Shaanxi prov-
ince is one of the most severely affected provinces in
China. Xi’an is the center district of Shaanxi province and
has had an increased incidence and mortality rate in the
last three years [6]. Until now, it has been reported that all
HFRS cases in this district are caused by hantaan virus
(HTNV), a major serotype of Hantavirus [6], and the dis-
ease usually occurs in the spring and autumn/winter, with
two incidence peaks [7]. Furthermore, a large number of
patients in this epidemic area were adults, which was in
sharp contrast to the predominantly pediatric cases seen
in the dengue epidemics in southeast Asia [8,9].
The clinical course of HFRS is primarily characterized by
fever, circulatory collapse with hypotension, hemorrhage
and acute kidney injury (AKI) [2,10]. The typical disease
progresses through five phases: febrile, hypotensive, oli-
guric, diuretic, and convalescent [11,12]. A hallmark of
HFRS is capillary leak syndrome, which causes edema and
hemorrhage, suggesting that the vascular endothelium is
the primary target of virus infection [13,14]. In view of the
rapidly expanding population and high mortality rate of in-
fection in this district [6], it is essential to obtain a more
comprehensive and better understanding of the clinical
characteristics and outcomes in critical patients with this
disease and to help clinicians engage in timely monitoring
and effective supportive therapy in the early stages of the
disease to improve the final survival rate.
Methods
Study participants
The medical charts of 356 typical HFRS patients who
were treated in the Center for Infectious Diseases, Tangdu
Hospital, between January 2008 and August 2012 were se-
lected randomly and reviewed. The diagnosis of HFRS was
made based upon the detection of specific IgM and IgG
antibodies to HTNV in acute phase serum specimens by
enzyme-linked immunosorbent assay (ELISA).
Based upon clinical classification of HFRS [15], the pa-
tients were classified into four types: (1) mild, defined
as patients who had kidney injury without oliguria
and hypotension; (2) moderate, defined as patients who
had uremia, effusion (bulbar conjunctiva), hypotension,
hemorrhage (skin and mucous membranes), and AKI with
typical oliguria; (3) severe, defined as patients who had
severe uremia, effusion (bulbar conjunctiva and either
peritoneum or pleura), hemorrhage (skin and mucous
membranes), hypotension and AKI with oliguria (urine
output of 50–500 mL/day) for ≤ 5 days or anuria (urine
output of < 100 mL/day) for ≤ 2 days; (4) critical, defined
as patients who usually had one or more of the following
complications compared with the severe patients: refractory
shock (≥ 2 days), visceral hemorrhage, heart failure, pul-
monary edema, brain edema, severe secondary infection,
and severe AKI with oliguria (urine output of 50–500 mL/
day) for > 5 days or anuria (urine output of < 100 mL/day)
for > 2 days. Commonly, the so-called acute stage of the
disease is defined as the period of febrile, hypotensive and
oliguric phases. Overall, 75 cases were classified as critical
type and were enrolled in this study. Furthermore, the out-
come was defined as death or survival during the interval
of being in hospital and after discharge with following up.
Laboratory and imaging studies
Laboratory and imaging results that documented the
clinical presentations and outcomes of the critical pa-
tients with HFRS complicated by ARDS were analyzed
and compared. Biochemical tests of blood samples were
performed using an autoanalyzer (Sysmex, XT-4000i,
Japan; Hitachi, 7600–100, Japan), including basic meta-
bolic, liver and renal function and glucose tests. Blood
clotting functions were tested using hematology ana-
lyzers (CA7000, Sysmex, Japan; ACL, TOP700, United
States). Chest and abdomen organs were visualized using
X-ray radiography (PLOYMOBIL 2.5, Siemens, Germany)
and ultrasonography (DC-6, MINDRAY, China). Com-
puted tomography (CT) (CTTM64, Siemens, Germany)
was performed in some patients. Cardiac function was
measured using Cardiofax (1350p, NIHON KOHDEN,
Japan) and ultrasonography (DC-7, MINDRAY, China).
Arterial blood gases were measured using an automatic
blood gas system (ABL80, Denmark). Hemo cultures were
tested using an autoanalyzer (BD9120, United States;
BD9050, United States).
Definition of HFRS-related complications
Acute renal failure (ARF) was defined as the third stage
of AKI according to the criteria of Acute Kidney Injury
Network (AKIN) [16]. Patients who had manifestations
of altered mental status (drowsiness, spasm, lethargy,
agitation, or coma) were defined as having encephalop-
athy. Patients who had manifestations of acute respiratory
distress including dyspnea, short breath, cyanosis accom-
panied with oxygenation index (PaO2/FiO2) ≤ 200 mmHg,
were defined as exhibiting ARDS [17]. Gastrointestinal
hemorrhage was defined as hematemesis or dark stools
with hemodynamic instability and a rapid decrease in
hemoglobin level to ≤ 7.0 g/dL. Secondary hypergly-
cemia was defined as an increase of blood-fasting sugar ≥
7.1 mmol/L without primary diabetes. Pneumonia was
clinically diagnosed according to the manifestations of
cough, expectoration and chest distress with confirmation
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by X-ray radiography or/and chest CT. Concurrent
bacteremia was defined as a positive bacterial growth
from blood that was sampled for culture within 72 h after
the patient was hospitalized. Secondary hypertension was
defined as systolic blood pressure (SBP) ≥ 140 mmHg dur-
ing the clinical course without primary hypertension. Car-
diac failure was defined as hypotension and tachycardia
based upon the fluid expansion with the confirmation
by cardiac ultrasonography and invasive hemodynamic
monitoring. Arrhythmia, including atrial premature beats,
ventricular premature contraction, atrial fibrillation, ven-
tricular fibrillation, supraventricular tachycardia, ventricu-
lar tachycardia and atrial ventricular block, was confirmed
by electrocardiography (ECG).
Statistical analysis
Statistical analysis was performed using SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Tables were created
using Excel 2003 (Microsoft), and figures were created using
GraphPad Prism 5 (GraphPad Software, San Diego CA).
Continuous variables are presented as the mean ± SD and
were analyzed by Kolmogorov-Smirnov’s test for nor-
mality of the distribution and Levene’s test for the homo-
geneity of variance. The variables were compared with
Student’s t-test for normally distributed variables. For non-
normally distributed variables, the nonparametric Mann–
Whitney U-test was used. The frequencies and percentages
are given for qualitative variables. Significant differences
were tested by the chi-square test, and Fisher’s exact test
was used when numbers were too small to perform the
chi-square test. Spearman’s correlation coefficient was used
to determine the relationship between the clinical manifes-
tations, laboratory values, complications and survival out-
come, respectively. Binary logistic regression analysis was
used to identify clinical risk factors for prognosis. Predict-
ing values for prognosis of the laboratory parameters were
tested with receiver operating characteristic (ROC) curves
and quantified by calculating the area under the curve
(AUC) and the 95% confidence interval (CI). Kaplan-Meier
analysis was used for the cumulative proportion surviving
and 28-day mortality rate in the critical patients. A two-
tailed P < .05 was considered statistically significant.
Ethics statement
This retrospective study was reviewed and approved by
the Institutional Review Board of Tangdu Hosipital, and
the patients’ medical records were anonymized and de-
identified prior to analysis.
Results
Clinical, demographic and epidemiologic conditions of
the critical patients
Of the 75 critical patients, 46 survived and 29 died; 59
patients (78.7%) were male, and 61 patients (81.3%) were
farmers. The mean age and sex were not significantly
different between survivors and non-survivors (P = .094
and P = .638, separately). There was also no significant
difference with regard to the seasonal incidence (October
to December), career, interval from the onset to the pa-
tient’s arrival, interval of febrile phase or the frequency of
overlapping hypotensive and oliguric phases (P > .05). The
survivors tended to have prolonged hospital days com-
pared with the non-survivors (P < .001) (Table 1).
Clinical manifestations, supportive treatments, imaging
and humoral examinations in the critical patients
Of the clinical symptoms and physical signs, the non-
survivors had higher frequencies of dyspnea, agitation,
conjunctival hemorrhage and coma (P = .049, P < .001,
P = .011, and P < .001, respectively) (Tables 2 and 3).
There were no significant differences with respect to
the supportive treatments, including the frequencies of
renal replacement therapy (RRT) and mechanic ventila-
tion (MV), imaging and humoral examinations, between
the survivors and non-survivors (P > .05) (Table 4).
HFRS-related complications in the critical patients
Of the HFRS-related complications, the frequencies
of cardiac failure, ARDS and encephalopathy in the
non-survivors were higher than those in the survivors
(P < .001), while the frequency of ARF in the survi-
vors was higher than that of the non-survivors (P = .013)
(Table 5). There were no significant differences with
respect to the frequencies of pneumonia, arrhythmia,
Table 1 Demographic, epidemiologic and clinical







Male/Female, n 37/9 22/7 .638
Mean Age, years 48.76 ± 13.59 53.90 ± 11.31 .094
Epidemiologic
characteristics




34 (72.3) 16 (55.2) .125
Clinical characteristics
Interval from onset to the
patient’s arrival, days
6.11 ± 6.99 4.93 ± 2.83 .391
Interval of febrile phase,
days




26 (56.5) 22 (75.9) .089
Hospital days, days 28.35 ± 13.28 7.97 ± 12.33 < .001
aSurvivors vs. non-survivors.
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Dyspnea, n (%) 12 (26.1) 14 (48.3) .049
Fever, n (%) 46 (100) 29 (100) 1.000
Nausea, n (%) 35 (76.1) 21 (72.4) .722
Vomiting, n (%) 27 (58.7) 17 (58.6) .995
Anepithymia, n (%) 12 (26.1) 4 (13.8) .206
Hematemesis, n (%) 5 (10.9) 2 (6.9) .866
Dark stools, n (%) 7 (15.2) 4 (13.8) .865
Abdominal distention, n (%) 23 (50) 13 (44.8) .662
Cough, n (%) 17 (37) 6 (20.7) .137
Expectoration, n (%) 13 (28.3) 4 (13.8) .145
Spasm, n (%) 3 (6.5) 3 (10.3) .875
Agitation, n (%) 16 (34.8) 24 (82.8) < .001
Fatigue, n (%) 21 (45.7) 10 (34.5) .339
Lethargy, n (%) 11 (23.9) 10 (34.5) .323
Hemoptysis, n (%) 2 (4.3) 2 (6.9) 1.000
Blurred vision, n (%) 3 (6.5) 3 (10.3) .875
Chills, n (%) 10 (21.7) 9 (31) .367
Diarrhea, n (%) 9 (19.6) 6 (20.7) .906
Stomachache, n (%) 19 (41.3) 11 (37.9) .772
Headache, n (%) 22 (47.8) 10 (34.5) .255
Dizziness, n (%) 13 (28.3) 9 (31) .797
Lumbago, n (%) 30 (65.2) 14 (48.3) .147
Chest distress, n (%) 22 (47.8) 13 (44.8) .800
Short breath, n (%) 22 (47.8) 17 (58.6) .362
aSurvivors vs. non-survivors.








39.38 ± 0.60 39.64 ± 0.63 .086
Neck and chest bleeding
point, n (%)
23 (50) 16 (55.2) .662
Conjunctival congestion, n (%) 44 (95.7) 28 (96.6) 1.000
Conjunctival hemorrhage, n (%) 7 (15.2) 12 (41.4) .011
Soft palate congestion, n (%) 42 (91.3) 26 (89.7) 1.000
Pharyngeal congestion, n (%) 37 (80.4) 21 (72.4) .419
Eyelid swollen, n (%) 13 (28.3) 10 (34.5) .569
Edema of lower limbs, n (%) 14 (30.4) 10 (34.5) .714
Blushing, n (%) 15 (32.6) 6 (20.7) .263
Positive shifting dullness, n (%) 11 (23.9) 2 (6.9) .058
Coma, n (%) 6 (13) 22 (75.9) <.001
Rash, n (%) 4 (8.7) 1 (3.4) .680
Petechiae, n (%) 26 (56.5) 17 (58.6) .858
aSurvivors vs. non-survivors.
Table 4 Supportive treatment, imaging and humoral







RRT, n (%) 42 (91.3) 22 (75.9) .132
CRRT, n (%) 28 (60.9) 22 (75.9) .180
MV, n (%) 15 (32.6) 7 (24.1) .433
Image manifestations
Pulmonary effusion, n (%) 31 (62.4) 17 (58.6) .441
Pleural effusion, n (%) 28 (60.9) 11 (37.9) .053
Seroperitoneum, n (%) 28 (60.9) 13 (44.8) .174
T-wave change, n (%) 6 (13) 3 (10.3) 1.000
Premature ventricular
contraction, n (%)
5 (10.9) 1 (3.4) .474
Atrial premature beats, n (%) 3 (6.5) 4 (13.8) .518
Atrial fibrillation, n (%) 5 (10.9) 3 (10.3) 1.000
Pericardial effusion, n (%) 13 (28.3) 3 (10.3) .065
Gallbladder swelling, n (%) 10 (21.7) 6 (20.7) .914
Humoral examinations
Urine protein +++ ~ ++++,
n (%)
33 (71.7) 22 (75.9) .694
Urine occult blood +++ ~ ++++,
n (%)
34 (73.9) 17 (58.6) .167
Abbreviations: RRT, renal replacement therapy; CRRT, continuous renal
replacement therapy; MV, mechanical ventilation.
aSurvivors vs. non-survivors.







ARDS, n (%) 17 (37.6) 25 (86.2) <.001
Pneumonia, n (%) 41 (89.1) 27 (93.1) .866
Arrhythmia, n (%) 9 (19.6) 8 (27.6) .419
Alimentary tract
hemorrhage, n (%)
17 (37) 17 (58.6) .066
Cardiac failure, n (%) 3 (6.5) 11(39.3) <.001
Hyperglycemia, n (%) 36 (78.3) 25 (86.2) .390
Encephalopathy, n (%) 11 (23.9) 28 (96.6) <.001
Concurrent bacteremia, n (%) 13 (28.3) 8 (27.6) .949
Secondary hypertension, n (%) 26 (56.5) 10 (34.5) .063
ARF, n (%) 42 (91.3) 20 (69.0) .013
Abbreviations: ARDS, acute respiratory distress syndrome; ARF, acute renal failure.
aSurvivors vs. non-survivors.
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gastrointestinal hemorrhage, hyperglycemia, concurrent
bacteremia or secondary hypertension (P > .05).
Laboratory parameters in the critical patients during the
acute stage
The levels of white blood cells (WBC), hemoglobin (HGB),
alanine aminotransferase (ALT), blood urea nitrogen
(BUN), serum creatinine (Scr), glucose, prothrombin
time (PT), activated partial thromboplastin time (APTT)
and thrombin time (TT) in the critical patients were
higher or longer than the reference value (P < .001), while
the levels of platelet (PLT) and serum albumin (ALB) were
lower than the reference value (P < .001) (Table 6). Com-
pared with the survivors, non-survivors were found to
have lower Scr levels (P < .001), prolonged PT (= 0.006)
and APTT (= 0.003) and more elevated WBC levels
(P = .005) (Table 6).
Spearman correlation and logistic regression analysis
Of the clinical manifestations, agitation, conjunctival
hemorrhage, and coma were negatively correlated with
the survival outcome (P < .05) (Table 7). Of the HFRS-
related complications, cardiac failure, ARDS and enceph-
alopathy were negatively correlated with the survival
outcome, while ARF was positively correlated with the
survival outcome (P < .05) (Table 7). Of the laboratory pa-
rameters, WBC, PT and APTT were negatively correlated
with the survival outcome, while Scr was positively corre-
lated with the survival outcome (P < .05) (Table 7).
To explore risk factors for prognosis, binary logistic re-
gression analysis was used to analyze the clinical symp-
toms, signs and complications that were correlated with
the survivor outcome. The prognosis of the critical pa-
tients was stratified with death defined as “1” and survival
defined as “0”. The clinical parameters were further strati-
fied and ranked according to their occurrence during the
clinical course. Finally, ARDS, conjunctival hemorrhage
and coma were identified as risk factors for prognosis,
with odds ratios (ORs) of 14.333, 17.640 and 25.716 re-
spectively (P < 0.05). Regression coefficients of the three
factors (Table 8) were used to calculate a logit of death
as follows:
The logarithm of odds of death
¼ ‐5:295þ 2:663 ARDS
þ 2:870 Conjunctival hemorrhage
þ 3:247 Coma
ROC and Kaplan-Meier survival analysis
Kaplan-Meier analysis was applied to determine the cumu-
lative proportion surviving and 28-day mortality rate in the
critical patients. The analysis revealed that the cumulative
proportion surviving was 70.7% at the second week inter-
val, with a 28-day mortality rate of 36.3% (Figure 1).
To explore the predicting value for prognosis on the la-
boratory parameters, ROC and AUC were analyzed. The
analysis revealed that the WBC and Scr levels and the PT
Table 6 Laboratory parameters in critical patients with HFRS during the acute stage
Variables Survivors (n = 46) Non-survivors (n = 29) P valuea
Mean ± SD nb Mean ± SD nb
Maximum WBC, 109 cells/L 34.43 ± 16.02c 39 47.95 ± 21.78c 26 .005
Nadir PLT, 109 cells/L 12.18 ± 11.16d 39 14.35 ± 10.28d 26 .432
Maximum HGB, g/L 171.00 ± 24.11c 39 166.92 ± 26.42c 25 .162
Maximum ALT, u/L 170.11 ± 210.92c 44 502.91 ± 859.69c 29 .213
Nadir serum ALB, g/L 24.53 ± 4.92d 44 22.45 ± 5.20d 29 .088
Maximum BUN, mmol/L 31.13 ± 8.58c 44 26.34 ± 12.77c 29 .084
Maximum Scr, μmol/L 778.46 ± 220.86c 44 479.66 ± 254.29c 29 <.001
Maximum glucose, mmol/L 13.32 ± 6.00c 43 15.34 ± 8.22c 28 .235
Longest PT, sec 15.20 ± 3.44c 45 20.53 ± 9.15c 28 .006
Longest APTT, sec 45.96 ± 14.79c 45 59.52 ± 19.94c 28 .003
Longest TT, sec 23.86 ± 6.24c 45 25.32 ± 6.72c 28 .282
Minimum Fib, g/L 1.84 ± 0.82d 44 1.46 ± 0.84d 29 .056
Reference values: WBC (3.2-9.7) × 109/L; PLT (100–300) × 109/L; HGB (120–160) g/L (male), (110–150) g/L (female); ALT (4–44) U/L; serum ALB (35–55) g/L; serum
BUN (2.86-8.20) mmol/L; serum Cr (53–97) μmol/L (male), (35–71) μmol/L (female); glucose (3.89-6.11) mmol/L; PT (8.8-13.8) sec; APTT (25.1-36.5) sec; TT (10.3-16.6)
sec, Fib (2.38-4.98) g/L.
Abbreviations: WBC, white blood cells; PLT, platelet; HGB, hemoglobin; ALT, alanine aminotransferase; ALB, albumin; BUN, blood urea nitrogen; Scr, serum
creatinine; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; Fib, fibrinogen.
aSurvivors vs. non-survivors.
bSome critical patients had passed through the acute stage on admission, and therefore, no laboratory data were available.
cHigher or longer than the reference value, P < .001.
dLower than the reference value, P < .001.
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and APTT times were statistically significant for predict-
ing prognosis (P < .05) (Figure 2, Table 9).
Discussion
To our knowledge, this is the first clinical study on the
clinical characteristics and outcomes in critical patients
with HFRS, with the largest sample enrolled in China. In
the 75 critical patients enrolled, 29 cases died, with a
hospital fatality of 38.7%. The Kaplan-Meier analysis re-
vealed that the cumulative proportion surviving was
70.7% at the second week interval, with a 28-day mortal-
ity rate of 36.3% (Figure 1). This observation indicated
that the fatality of critical patients with HFRS was high
and was similar to the mortality rate of severe septic
shock patients in the intensive care unit (ICU) [18-20].
In this study, a majority of patients enrolled were male
and farmers, with high incidence and obvious seasonal
distribution (Table 1). These data are consistent with the
biological and epidemical characteristics of the primary
natural host (Apodemus agrarius) of HTNV and the sus-
ceptibility of the patients working in certain surround-
ings that are the natural habitat of rodents in Xi'an city
[6,7,21]. Until now, the hantavirus strains from host ro-
dents and patients in Xi’an only belong to the HTNV,
and SEOV strains have not been found [6].
In this study, the survivors tended to have prolonged
hospital stays (Table 1), which were consistent with the
clinical course of HFRS. Generally, the hypotensive
phase of HFRS (e.g., low blood pressure and circulation
collapse) usually occurs between day 3 and day 7 of the
clinical course, and some critical patients even exhibit
overlapping hypotensive and oliguric phases combined
with various fatal complications. During this period, timely
and systematically supportive treatment, including mech-
anical ventilation combined with continuous blood purifi-
cation (CBP), vasoactive drugs and nutritional supplement,
Table 7 Spearman correlation analysis in critical patients
with HFRS
Survival Survival
Parameters r P value Parameters r P value
Agitation -.468 < .001 Encephalopathy -.743 < .001
Conjunctival
hemorrhage
-.293 .011 ARF .287 .012
Coma -.632 < .001 WBC -.330 .006
Dyspnea -.227 .051 Scr .550 < .001
ARDS -.512 < .001 PT -.370 .001
Cardiac failure -.393 < .001 APTT -.362 .002
Abbreviations: r, correlation coefficient; ARDS, acute respiratory distress
syndrome; ARF, acute renal failure; WBC, white blood cells; Scr, serum
creatinine; PT, prothrombin time; APTT, activated partial thromboplastin time.
Table 8 Independent risk factors for death in critical
patients with HFRS
Parameters B SE Wald df P OR 95% CI for OR
Lower Upper
ARDS 2.663 1.215 4.799 1 .028 14.333 1.324 155.222
Conjunctival
hemorrhage
2.870 1.064 7.275 1 .007 17.640 2.191 141.989
Coma 3.247 .927 12.257 1 .000 25.716 4.176 158.372
Constant −5.295 1.641 10.409 1 .001 .005
Forward: conditional; Omnibus Test of Coefficients: Chi-square 53.226, P < .001.
Abbreviations: B, independent variable coefficient; SE, standard error; CI, confidence
interval; df, degrees of freedom; OR, odds ratio.
Figure 1 The Kaplan-Meier survival analysis is based on the
total survival time in the period from the onset of illness to
discharge or death in the critical patients with HFRS. The event
of interest was defined as patient death during hospitalization and
patient discharge as censored. Of the 75 critical patients, the
cumulative proportion surviving of 85.3% at the first week interval,
70.7% at the second week interval, 65.1% at the third week interval
and 63.7% at the fourth week interval.
Figure 2 ROC analysis of WBC, Scr, PT and APTT revealed that
the four parameters reached statistical significance for
predicting prognosis (P < .05). Abbreviations: ROC, receiver
operating characteristic; WBC, white blood cells; PT, prothrombin
time; APTT, activated partial thromboplastin time; Scr, creatinine.
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are necessary to ensure survival. However, some critical
patients still died of refractory shock, ARDS, multiorgan
bleeding, disseminated intravascular coagulation (DIC) or
multiple organ dysfunction syndrome (MODS). Patients
who have passed through the critical phase may manifest
obvious oliguria with AKI. The durations of the oliguric
phase in patients with HFRS are obviously different based
upon the degree of AKI [16] and the influence on applica-
tions of RRT including continuous renal replacement ther-
apy (CRRT) and intermittent hemodialysis (IHD) [22,23];
only a minority of critical patients die during this phase.
Furthermore, it is an unfortunate truth that in addition to
the critical condition of the disease on admission, the pa-
tient’s economic status may also influence the prognosis
directly or indirectly.
The present study demonstrated that the non-survivors
had higher frequencies of dyspnea, agitation, conjunctival
hemorrhage, coma, cardiac failure, ARDS and encephalop-
athy compared to the survivors (Tables 2, 3, 4 and 5). The
agitation, conjunctival hemorrhage, coma, cardiac failure,
ARDS and encephalopathy were all negatively correlated
with the survival outcome (Table 7). Although there was
no significant relationship, the difference was obvious in
pleural effusion and pericardial effusion found in the sur-
vivors vs. non-survivors (Table 4). According to the patho-
physiologic characteristics of HFRS, the pleural and
pericardial effusion can reflect the degree of body edema
and may increase the risk of the occurrence of pulmonary
infection, ARDS and heart failure. All of these findings
highlight that it would be dangerous to ignore the critical
condition of the disease and the increased probability of
death when patients exhibit clinical manifestations of
ARDS and encephalopathy, and conjunctival hemorrhage
can be considered to be a local manifestation of severe
organ bleeding with poor outcome. Furthermore, ARDS,
conjunctival hemorrhage and coma were identified as risk
factors for prognosis by binary logistic regression analysis
(Table 8), which underscores the importance of clinicians’
alertness to the occurrence of potentially fatal complica-
tions. Additionally, although cardiac failure was not a risk
factor for death in the present report, it deserves further
study in larger samples of critical patients, especially the
cases of deaths.
Kidney is a major organ that is damaged during HFRS,
with the most prominent pathological presentation being
acute tubulointerstitial nephritis following the infiltra-
tion of inflammatory cells [24]. In this study, a majority
of the patients had humoral abnormalities with obvious
urine protein and urine occult blood (Table 4), which may
reflect the degree of severity of AKI. In this study, all the
critical patients had different stages of AKI, and 62 cases
(82.7%) exhibited ARF, the third stage of AKI [16] (Table 5).
Interestingly, we observed that the frequency of ARF in the
survivors was obviously higher than that of the non-
survivors (Table 5). ARF and Scr were positively correlated
with the survival outcome (Table 7); non-survivors were
also found to have lower Scr levels (Table 6).These results
can be explained by the fact that some critical patients died
during the overlapping phase because of other fatal com-
plications when ARF was not obviously detected. Accord-
ing to the data, we can conclude that the stage of AKI and
the duration of the oliguric phase during the acute stage
are not a directly influential factor for prognosis because of
the application of RRT.
This study observed that the levels of WBC, HGB,
ALT, BUN, Scr, glucose, PT, APTT and TT in the critical
patients were higher or longer than the reference value,
while the levels of PLT and ALB were lower than the refer-
ence value (Table 6), which indicated that critical patients
with HFRS usually had obvious hepatic and kidney injury,
and stress hyperglycemia and hypermetabolism were also
common during the clinical course. According to the path-
ophysiologic mechanism of HFRS, it has been widely ac-
cepted that severe plasma leakage, massive bleeding and/or
profound shock may lead to tissue hypoperfusion, poten-
tially rendering AKI and hepatic injury [25]; the high level
of HGB was closely related to the degree of pachyhemia;
the low level of PLT was related to the decreased platelet
production or increased platelet destruction [26-28]; the
low level of ALB correlates with degree of the loss of vas-
cular integrity and enhanced vascular permeability, which
also usually appears in patients with dengue hemorrhagic
Table 9 Predictive values for prognosis on laboratory parameters in critical patients with HFRS
Parameters AUC P valuea Cut-off value Sensitivityb Specificityb 95% Cl for AUCb
Lower Upper
WBC 0.688 0.012 46.05 60.0 82.1 54.4 83.2
Scrc 0.828 0.001 586.7 76.0 84.1 72.7 93.0
PT 0.724 0.003 15.60 88.0 59.0 59.3 85.6
APTT 0.710 0.005 52.10 69.0 69.2 58.0 84.0
Abbreviations: AUC, area under the curve; CI, confidence interval.
aP value for calculated AUC in predicting death.
bSensitivity, specificity and 95% CI are all presented as percentages.
cTest direction: lower test result indicates a more positive test.
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fever (DHF) [3,29]. Compared to the survivors, the non-
survivors were found to be more critical, with a higher
degree of inflammatory reaction and coagulation abnor-
mality, which is in line with the previous reports on pa-
tients with DHF [30-32]. Furthermore, although the AUCs
were not higher than 0.900 and would be influenced by
small samples or treatments, ROC analysis still revealed
that the WBC levels, PT and APTT times were statistically
significant for predicting death (Table 9, Figure 2). In total,
the laboratory results may reflect the severity of the
disease to a degree, and clinicians should be alert to
their dynamic changes during the acute stage, ensure
close monitoring and thereby initiate a timely manage-
ment as necessary.
As a retrospective study, some limitations must be ad-
dressed. First, this study was conducted at the largest
center for infectious diseases in the northwest region of
China. Most patients with severe clinical conditions
were sent to our medical center, but it is likely that out-
side of our center, there were still a significant number
of critical HFRS patients who were admitted to local
hospitals. Therefore, the demographic, epidemiological
characteristics and mortality rate in critical patients may
have been biased. Second, the clinical manifestations
may be biased by clinicians based on his or her personal
recognition of the clinical severity. In this study, we were
unable to calculate the acute physiology, age, chronic
health evaluation (APACHE II) score, sepsis related organ
failure assessment (SOFA) and simplified acute physiology
score (SAPS II) of the critical patients on admission
because of the loss of detailed clinical data on central
nervous system dysfunction. These data may be very im-
portant for predicting the prognosis. Third, the relatively
small number of cases made the statistical power quite
small, especially for multivariate logistic regression
analysis used for identifying risk factors for death in
the critical patients. Finally, the clinical outcomes and
classifications of HFRS patients might be biased by
the lack of a more standardized protocol for the man-
agement of patients with HFRS.
Conclusion
The high fatality in critical patients with HFRS under-
scores the importance of clinicians’ alertness to the occur-
rence of potentially fatal complications and changes in
biochemical status to ensure that timely and systematically
supportive treatment can be initiated when necessary.
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